--- title: "Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280551738.md" description: "Hong Kong's biopharmaceutical sector saw significant stock gains amid market volatility, with XuanZhu Biopharma-Brising over 12%, Ascletis Pharmaincreasing by more than 7%, and both Lepu Biopharmaand XtalPi Holdingsclimbing over 6%. Akeso Biopharmaalso saw a rise of 5.5%. This trend indicates a positive outlook for the biopharmaceutical industry in Hong Kong's stock market." datetime: "2026-03-26T01:51:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280551738.md) - [en](https://longbridge.com/en/news/280551738.md) - [zh-HK](https://longbridge.com/zh-HK/news/280551738.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280551738.md) | [English](https://longbridge.com/en/news/280551738.md) # Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility Hong Kong's biopharmaceutical sector experienced notable gains as several stocks surged amid market fluctuations. According to Jin10, XuanZhu Biopharma-B (02575.HK) saw an increase of over 12%, while Ascletis Pharma (01672.HK) rose by more than 7%. Additionally, Lepu Biopharma (02157.HK) and XtalPi Holdings (02228.HK) both climbed over 6%, and Akeso Biopharma (09926.HK) increased by 5.5%. These movements reflect a positive trend in the biopharmaceutical industry within Hong Kong's stock market. ### 相關股票 - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [ASCLETIS-B (01672.HK)](https://longbridge.com/zh-HK/quote/01672.HK.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [XTALPI (02228.HK)](https://longbridge.com/zh-HK/quote/02228.HK.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [AKESO (09926.HK)](https://longbridge.com/zh-HK/quote/09926.HK.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [LEPU BIO-B (02157.HK)](https://longbridge.com/zh-HK/quote/02157.HK.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [XUANZHUBIO-B (02575.HK)](https://longbridge.com/zh-HK/quote/02575.HK.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) ## 相關資訊與研究 - [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-HK/news/281068292.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md) - [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-HK/news/280923090.md) - [Akeso FY revenue RMB 3,056.3 million](https://longbridge.com/zh-HK/news/280664190.md) - [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/zh-HK/news/280992698.md)